Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.

Upstream Bio, Inc. Common Stock

At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones.

HBM Healthcare Investments AG

Omega Funds

OrbiMed

Samsara BioCapital

Maruho

Access Biotechnology

Altshuler Shaham

TCG Crossover

Decheng Capital

Wellington Management

HBM Partners

Bain Capital Life Sciences

Venrock Healthcare Capital Partners

Enavate Sciences

Upstream Bio

COM:UPSTREAMBIO